Therapeutic review: The basis of an intracrine pharmacology

Journal of Clinical Pharmacology

Volumn 48, Issue 3, 2008, Pages 344-350

  Re, Richard N ^a   Cook, Julia L ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

Angiogenesis; Angiotensin; Differentiation; Intracrine

Indexed keywords

ACTIBIND; ALISKIREN; ANGIOGENIN; ANGIOSTATIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CANDESARTAN; CONSTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA BINDING PROTEIN; ENDOSTATIN; ENZYME; GEFITINIB; GROWTH FACTOR; HORMONE; INTEGRIN ANTIBODY; LACTOFERRIN; LOSARTAN; NEAMINE; PACLITAXEL; PARATHYROID HORMONE RELATED PROTEIN; PEPTIDE; PSEUDOLORIX ACID B; RETINA S ANTIGEN; TELMISARTAN; TRASTUZUMAB; TUMSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; SIGNAL PEPTIDE;

ANGIOGENESIS; CELL DIFFERENTIATION; DRUG ACTIVITY; DRUG DESIGN; HEMATOPOIETIC STEM CELL; HUMAN; HYPERTENSION; NONHUMAN; PHARMACOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PHYSIOLOGIC; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 39149092333     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007312155     Document Type: Review

References (46)

1. Re R., Bryan SE Functional intracellular rennin-angiotensin systems may exist in multiple tissues. Clin Exp Hypertens A. 1984 ; 6: 1739-1742.
2. Re RN The cellular biology of angiotensin: paracrine, autocrine, and intracrine actions in cardiovascular tissues. J Mol Cell Cardiol. 1989 ; 21 (suppl V). 63-69.
3. Re RN The nature of intracrine peptide hormone action. Hypertension. 1999 ; 34: 534-538.
4. Re RN The origins of intracrine hormone action. Am J Med Sci. 2002 ; 323: 43-48.
5. Re RN Toward a theory of intracrine hormone action. Regul Pept. 2002 ; 106: 1-6.
6. Re RN The intracrine hypothesis and intracellular peptide hormone action. Bioessays. 2003 ; 25: 401-409.
7. Re RN, Cook JL The intracrine hypothesis: an update. Regul Pept. 2005 ; 133: 1-9.
8. Lee TH, Seng S., Sekine M., et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007 ; 4: e186.
9. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004 ; 103: 3883-3889.
10. Ventura C., Branzi A. Autocrine and intracrine signaling for cardiogenesis in embryonic stem cells: a clue for the development of novel differentiating agents Handb Exp Pharmacol. 2006 ; 174: 123-146.
11. Dori A., Soreq H. ARP, the cleavable C-terminal peptide of "readthrough" acetylcholinesterase, promotes neuronal development and plasticity. J Mol Neurosci. 2006 ; 28: 247-255.
12. Re RN Intracellular renin and the nature of intracrine enzymes. Hypertension. 2003 ; 42: 117-122.
13. Nguyen G. The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens. 2007 ; 16: 129-133.
14. Schefe JH, Menk M., Reinemund J., et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res. 2006 ; 99: 1355-1366.
15. Cook JL, Zhang Z., Re RN In vitro evidence for an intracellular site of angiotensin action. Circ Res. 2001 ; 89: 1138-1146.
16. Cook JL, Re R., Alam J., Hart M., Zhang Z. Intracellular angiotensin fusion protein alters AT1 receptor fusion protein distribution and activates CREB. J Mol Cell Cardiol. 2004 ; 36: 75-90.
17. Cook JL, Giardina JF, Zhang Z., Re RN Intracellular angiotensin II increases the long isoform of PDGF mRNA in rat hepatoma cells. J Mol Cell Cardiol. 2002 ; 34: 1525-1537.
18. Cook JL, Mills SJ, Naquin R., Alam J., Re RN Nuclear accumulation of the AT(1) receptor in a rat vascular smooth muscle cell line: effects upon signal transduction and cellular proliferation. J Mol Cell Cardiol. 2006 ; 40: 696-707.
19. Kumar R., Singh VP, Baker KM The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab. 2007 ; 18: 208-214.
20. Singh VP, Le B., Bhat VB, Baker KM, Kumar R. High glucose induced regulation of intracellular angiotensin II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007 ; 293: H939 - H948.
21. Re RN The intracellular renin angiotensin system: the tip of the intracrine physiology iceberg. Am J Physiol Heart Circ Physiol. 2007 ; 293: H905 - H906.
22. Ritter CA, Perez-Torres M., Rinehart C., et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network Clin Cancer Res. 2007 ; 13: 4909-4919.
23. Ferrer-Soler L., Vazquez-Martin A., Brunet J., Menendez JA, De Llorens R., Colomer R. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: gefitinib (Iressa)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands. Int J Mol Med. 2007 ; 20: 3-10.
24. Yoshioka N., Wang L., Kishimoto K., Tsuji T., Hu GF A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci U S A. 2006 ; 103: 14519-14524.
25. Hirukawa S., Olson KA, Tsuji T., Hu GF Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. Clin Cancer Res. 2005 ; 11 (24 Pt 1). 8745-8752.
26. Hu GF Neomycin inhibits the angiogenic activity of fibroblast and epidermal growth factors. Biochem Biophys Res Commun. 2001 ; 287: 870-874.
27. Re RN Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2004 ; 1: 42-47.
28. Re RN, Cook JL Intracrine physiology in the cardiovascular system. Nat Clin Pract Cardiovasc Med. 2007 ; in press.
29. Messerli FH, Re RN Do we need yet another blocker of the rennin-angiotensin system ? J Amer Col Cardiol. 2007 ; 49: 1164-1165.
30. Juillerat-Jeanneret L., Celerier J., Chapuis Bernasconi C, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer. 2004 ; 90: 1059-1068.
31. Kurtz TW Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol. 2005 ; 42 (suppl 1). S9 - S16.
32. Chen L., Re RN, Prakash O., Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med. 1991 ; 196: 280-283.
33. Re RN, Cook JL An intracrine view of angiogenesis. Bioessays. 2006 ; 28: 943-953.
34. Re RN, Cook JL Potential therapeutic implications of intracrine angiogenesis. Med Hypotheses. 2007 ; 69: 414-421.
35. Shi H., Huang Y., Zhou H., et al. Nucleolin is a receptor that mediates antiangiogenic and anti-tumor activity of endostatin. Blood. 2007 ; 110: 2899-2906.
36. Schwartz B., Shoseyov O., Melnikova VO, et al. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Res. 2007 ; 67: 5258-5266.
37. Prochiantz A., Joliot A. Can transcription factors function as cell-cell signalling molecules ? Nat Rev Mol Cell Biol. 2003 ; 4: 814-819.
38. Noguchi H., Kaneto H., Weir GC, Bonner-Weir S. PDX-1 protein containing its own antennapedia-like protein transduction domain can transduce pancreatic duct and islet cells. Diabetes. 2003 ; 52: 1732-1737.
39. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006 ; 126: 663-676.
40. Okita K., Ichisaka T., Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature. 2007 ; 448: 313-317.
41. Maherali N., Sridharan R., Xie W., et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution. Cell Stem Cell. 2007 ; 1: 55-70.
42. Wernig M., Meissner A., Foreman R., et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007 ; 448: 318-324.
43. Re RN The implications of intracrine hormone action for physiology and medicine. Am J Physiol Heart Circ Physiol. 2003 ; 284: H751 - H757.
44. Ivanov S., Dragoi AM, Wang X., et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 2007 ; 110 (6). 1970-1981.
45. Joo EJ, ten Dam GB, van Kuppevelt TH, Toida T., Linhardt RJ, Kim YS Nucleolin: acharan sulfate-binding protein on the surface of cancer cells. Glycobiology. 2005 ; 15: 1-9.
46. Girvan AC, Teng Y., Casson LK, et al. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther. 2006 ; 5: 1790-1799.